CHina Adrenal Venous saMPling InvestigatiON (CHAMPION)

November 19, 2025 updated by: Hui DONG, Chinese Academy of Medical Sciences, Fuwai Hospital

China Adrenal Venous Sampling Investigation: A National Multicenter Study

Primary aldosteronism (PA) is a major cause of secondary hypertension, yet its optimal diagnosis and management remain challenging. This study comprehensively evaluates adrenal venous sampling (AVS), addressing key clinical, technical, and methodological issues, and aims to clarify the relationship between AVS-guided management and long-term clinical and biochemical outcomes to optimize patient care and prognosis.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Primary aldosteronism (PA) is one of the most common causes of secondary hypertension, yet its optimal diagnostic and therapeutic strategies remain challenging. Adrenal venous sampling (AVS) is regarded as the gold standard for subtype differentiation; however, important clinical, technical, and methodological issues have not been systematically addressed. This study is designed to comprehensively evaluate AVS and its clinical implications, aiming to elucidate the relationship between AVS-guided diagnosis and management of PA and long-term clinical and biochemical outcomes, while refining AVS protocols, standardizing clinical practice, optimizing therapeutic decision-making, and ultimately improving patient management and prognosis.

Study Type

Observational

Enrollment (Estimated)

5000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • China
    • Anhui
      • Hefei, Anhui, China, 230036
        • Recruiting
        • The First Affiliated hospital of USTC
        • Contact:
        • Principal Investigator:
          • Xiangyong Kong, PhD
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100034
        • Recruiting
        • Peking University First Hospital
        • Principal Investigator:
          • Wei Ma, MD
        • Contact:
      • Beijing, Beijing Municipality, China, 100044
        • Recruiting
        • Peking University People's Hospital
        • Contact:
        • Principal Investigator:
          • Jing Liu, MD
      • Beijing, Beijing Municipality, China, 100029
        • Recruiting
        • China-Japan Friendship Hospital
        • Principal Investigator:
          • Wuqiang Che, MD
        • Contact:
      • Beijing, Beijing Municipality, China, 100022
        • Recruiting
        • Chuiyangliu Hospital affiliated to Tsinghua University
        • Principal Investigator:
          • Lin Pi, MD
        • Contact:
      • Beijing, Beijing Municipality, China, 100037
        • Recruiting
        • Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College
        • Principal Investigator:
          • Hui Dong, MD
        • Contact:
        • Contact:
      • Beijing, Beijing Municipality, China, 101100
        • Recruiting
        • Beijing Luhe Hospital, Capital Medical University
        • Contact:
        • Principal Investigator:
          • Dong Zhao, MD, PhD
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, China, 400000
        • Recruiting
        • Chongqing University Central Hospital
        • Principal Investigator:
          • Dongying Zhang, MD
        • Contact:
      • Chongqing, Chongqing Municipality, China, 401147
        • Recruiting
        • Chongqing General Hospital
        • Principal Investigator:
          • Rui He, MM
        • Contact:
      • Chongqing, Chongqing Municipality, China, 404100
        • Recruiting
        • People's Hospital Affiliated to ChongqingThree Gorges Medical college
        • Principal Investigator:
          • Xianhu Luo, MD
        • Contact:
    • Fujian
      • Fuzhou, Fujian, China, 0591-87982222
        • Recruiting
        • First Affiliated Hospital, Fujian Medical University, Fuzhou, China,
        • Contact:
        • Principal Investigator:
          • Feng Peng, MD
      • Xiamen, Fujian, China, 361016
        • Recruiting
        • Cardiovascular Hospital Xiamen University
        • Principal Investigator:
          • Tao Ye, MD
        • Contact:
    • Gansu
      • Lanzhou, Gansu, China, 730000
        • Recruiting
        • Lanzhou University Second Hospital
        • Principal Investigator:
          • Wei Liang, MD
        • Contact:
    • Guangdong
      • Foshan, Guangdong, China, 528211
        • Recruiting
        • The Forth People's Hosptal of Nanhai District of Foshan City
        • Principal Investigator:
          • Yayan Han, MD
        • Contact:
      • Guangzhou, Guangdong, China, 510080
        • Recruiting
        • Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences)
        • Principal Investigator:
          • Yingqing Feng, MD
        • Contact:
      • Shenzhen, Guangdong, China, 518000
        • Recruiting
        • Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen
        • Contact:
        • Principal Investigator:
          • Jianqiong Kong, MD
      • Shenzhen, Guangdong, China, 518112
        • Recruiting
        • Shenzhen Third People's Hospital，Shenzhen, Guangdong Province 518112, China
        • Contact:
        • Principal Investigator:
          • Zhenzhong Zheng, MD, PhD
      • Shenzhen, Guangdong, China, 518116
        • Recruiting
        • Shenzhen Dapeng New District Kuiyong People's Hospital
        • Principal Investigator:
          • Tongqing Lu, MD
        • Contact:
    • Guangxi
      • Nanning, Guangxi, China, 530000
        • Recruiting
        • The First Affiliated Hospital of Guangxi Medical University
        • Principal Investigator:
          • Jiangnan Huang, MD
        • Contact:
      • Nanning, Guangxi, China, 530007
        • Recruiting
        • The Second Affliated Hospital Of GuangXi Medical Univesity
        • Contact:
        • Principal Investigator:
          • Houfa Ning, MM
      • Nanning, Guangxi, China, 547000
        • Recruiting
        • Nanning Third People's Hospital
        • Contact:
          • Yongqi Xiao, MBBS
          • Phone Number: 07713394390
        • Principal Investigator:
          • Yongqi Xiao, MBBS
    • Guizhou
      • Guiyang, Guizhou, China, 550004
        • Recruiting
        • The Affiliated Hospital of Guizhou Medical University
        • Contact:
        • Principal Investigator:
          • Zhangrong Chen, MD
      • Guiyang, Guizhou, China, 550002
        • Recruiting
        • Guizhou Provincial People's Hospital, Guiyang, Guizhou 550002, China.
        • Contact:
        • Principal Investigator:
          • Fang Song, MD
      • Kaili, Guizhou, China, 556000
        • Recruiting
        • The Second Affiliated Hospital of Guizhou Medical University
        • Principal Investigator:
          • Yumei Xiang, MD
        • Contact:
    • Hainan
      • Haikou, Hainan, China, 570311
        • Recruiting
        • Hainan General Hospital, Department of Endocrinology
        • Contact:
        • Principal Investigator:
          • Haiyu Zhang, MM
      • Hainan, Hainan, China, 570311
        • Recruiting
        • Hainan General Hospital, Department of Cardiology
        • Contact:
        • Principal Investigator:
          • Wang Liao, MD
    • Hebei
      • Tangshan, Hebei, China, 063000
        • Recruiting
        • Tangshan hongci Hospital
        • Principal Investigator:
          • Guijuan Zhang, MD
        • Contact:
    • Heilongjiang
      • Harbin, Heilongjiang, China, 150086
        • Recruiting
        • The Second Affiliated Hospital of Harbin Medical University
        • Contact:
        • Principal Investigator:
          • Shuo Zhang, MD
      • Harbin, Heilongjiang, China, 150001
        • Recruiting
        • The First Affiliated Hospital of Harbin Medical University
        • Principal Investigator:
          • Dechao Zhao, MD
        • Contact:
    • Henan
      • Kaifeng, Henan, China, 475002
        • Recruiting
        • Kai Feng the Peoples Hospital
        • Contact:
        • Principal Investigator:
          • Qingli Pan, MD
      • Zhengzhou, Henan, China, 450052
        • Recruiting
        • the First Affiliated Hospital of Zhengzhou University
        • Contact:
        • Principal Investigator:
          • Youyou Du, MD
      • Zhengzhou, Henan, China, 450003
        • Recruiting
        • Henan Provincial People's Hospital
        • Principal Investigator:
          • Min Liu, MD
        • Contact:
      • Zhengzhou, Henan, China, 450000
        • Recruiting
        • Fuwai Central China Cardiovascular Hospital
        • Principal Investigator:
          • Qiuping Zhao, PhD
        • Contact:
      • Zhengzhou, Henan, China, 450018
        • Recruiting
        • Zhengzhou Yihe Hospital
        • Contact:
        • Principal Investigator:
          • Liang An, MD
      • Zhengzhou, Henan, China, 450007
        • Recruiting
        • Zhengzhou Central Hospital Affiliated to Zhengzhou University
        • Principal Investigator:
          • Shuhua Yu, MM
        • Contact:
      • Zhoukou, Henan, China, 466000
        • Recruiting
        • Zhoukou Central Hospital
        • Principal Investigator:
          • Baogong Wang, MD
        • Contact:
    • Hubei
      • Wuhan, Hubei, China, 430060
        • Recruiting
        • Renmin Hospital of Wuhan University
        • Contact:
        • Principal Investigator:
          • Hongxin Xu, MD
      • Xiangyang, Hubei, China, 441021
        • Recruiting
        • Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science
        • Contact:
        • Principal Investigator:
          • Qingan Li, MD
      • Yichang, Hubei, China, 43000
        • Recruiting
        • Yichang Central People's Hospital
        • Principal Investigator:
          • Yunbo Lv, MD
        • Contact:
    • Hunan
      • Zhuzhou, Hunan, China, 412000
        • Recruiting
        • Zhuzhou Hospital Affiliated to Xiangya School of Medicine,Central South University
        • Contact:
          • Liang Tang, MBBS
          • Phone Number: 0733-28561703
        • Principal Investigator:
          • Liang Tang, MBBS
    • Jiangsu
      • Xuzhou, Jiangsu, China, 221009
        • Recruiting
        • Xuzhou Central Hospital, Jiangsu
        • Contact:
        • Principal Investigator:
          • Hongyun Ruan, MD
    • Jiangxi
      • Ganzhou, Jiangxi, China, 341000
        • Recruiting
        • The First Affiliated Hospital of Gannan Medical University
        • Contact:
        • Principal Investigator:
          • Jiayuan Yuan, MD
      • Nanchang, Jiangxi, China, 330006
        • Recruiting
        • Second Affiliated Hospital of Nanchang University
        • Contact:
        • Principal Investigator:
          • Yifei Dong, MD, PhD
      • Nanchang, Jiangxi, China, 330038
        • Recruiting
        • Jiangxi Provincial People's Hospital (The First Affiliated Hospital of Nanchang Medical College)
        • Principal Investigator:
          • Haohang Ruan, MBBS
        • Contact:
          • Haohang Ruan, MBBS
          • Phone Number: 0791-87721036
    • Jilin
      • Changchun, Jilin, China, 130021
        • Recruiting
        • The First Hospital of Jilin University
        • Contact:
        • Principal Investigator:
          • Wei Zhao, MD
      • Changchun, Jilin, China, 130051
        • Recruiting
        • Jilin Province FAW General Hospital
        • Principal Investigator:
          • Wenhai Wang, MM
        • Contact:
    • Liaoning
      • Dalian, Liaoning, China, 116027
        • Recruiting
        • The Second Hospital of Dalian Medical University
        • Contact:
        • Principal Investigator:
          • Nan Niu, MD
      • Dalian, Liaoning, China, 116001
        • Recruiting
        • Affilated Zhongshan Hospital of Dalian University
        • Contact:
        • Principal Investigator:
          • Minglian Gong, MD
      • Dalian, Liaoning, China, 116011
        • Recruiting
        • Frist Aiffiliated Hospital of Dalian Medical University
        • Principal Investigator:
          • Yinong Jiang, MD
        • Contact:
    • Neimenggu
      • Ulanhot, Neimenggu, China, 137400
        • Recruiting
        • Inner Mongolia Xing'an League People's Hospital
        • Contact:
        • Principal Investigator:
          • Tao Guo, MM
    • Ningxia
      • Yinchuan, Ningxia, China, 750000
        • Recruiting
        • The First People's Hospital of Yinchuan
        • Contact:
        • Principal Investigator:
          • Fang Chen, PhD
    • Qinghai
      • Xining, Qinghai, China, 810001
        • Recruiting
        • Qinghai University Affiliated Hospital
        • Contact:
        • Principal Investigator:
          • Ming Ren, MM
      • Xining, Qinghai, China, 810000
        • Recruiting
        • Qinghai Province Cardiovascular and Cerebrovascular Disease Specialist Hospital
        • Contact:
        • Principal Investigator:
          • Xiaozhou Wang, MD
    • Shandong
      • Jinan, Shandong, China, 250012
        • Recruiting
        • Qilu Hospital of Shandong University
        • Principal Investigator:
          • Peili Bu, MD
        • Contact:
      • Jinan, Shandong, China, 250013
        • Recruiting
        • Central Hospital Affiliated to Shandong First Medical University
        • Contact:
        • Principal Investigator:
          • Rui Xu, MD, PhD
      • Jinan, Shandong, China, 250000
        • Recruiting
        • The Second Hospital, Cheeloo College of Medicine, Shandong University
        • Contact:
        • Principal Investigator:
          • Qinghai Wang, MD
      • Liaocheng, Shandong, China, 252200
        • Recruiting
        • People's Hospital of Donga County, Shandong Province
        • Principal Investigator:
          • Xiaoli Wang, MD
        • Contact:
      • Qingdao, Shandong, China, 266000
        • Recruiting
        • Qingdao Hospital University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital)
        • Contact:
        • Principal Investigator:
          • Nan Jia, MD
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200025
        • Recruiting
        • Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine
        • Contact:
        • Principal Investigator:
          • Jianzhong Xu, MD, PhD
      • Shanghai, Shanghai Municipality, China, 200062
        • Recruiting
        • Shanghai Putuo District Central Hospital
        • Principal Investigator:
          • Zongjun Liu, MD
        • Contact:
      • Shanghai, Shanghai Municipality, China, 200080
        • Recruiting
        • Shanghai General Hospital ( originally named Shanghai First People's Hospital), Shanghai Jiao Tong University School of Medicine
        • Contact:
        • Principal Investigator:
          • Zhi Zhang, MD
    • Shanxi
      • Taiyuan, Shanxi, China, 030001
        • Recruiting
        • the second hospital of ShanXi medical unversity
        • Principal Investigator:
          • Bin Yang, MD
        • Contact:
      • Xi’an, Shanxi, China, 710018
        • Recruiting
        • Xi'an People's Hospital
        • Contact:
        • Principal Investigator:
          • Kang Cheng, MD, PhD
    • Sichuan
      • Chengdu, Sichuan, China, 611130
        • Recruiting
        • Chengdu Fifth People's Hospital
        • Principal Investigator:
          • Mingjian Lang, MD
        • Contact:
      • Chengdu, Sichuan, China, 610500
        • Recruiting
        • The First Affiliated Hospital of Chengdu Medical College
        • Principal Investigator:
          • Peijian Wang, MD
        • Contact:
      • Chengdu, Sichuan, China, 610031
        • Recruiting
        • The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, China
        • Principal Investigator:
          • Zhen Zhang, MD
        • Contact:
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, China, 300052
        • Recruiting
        • Tianjin Medical University General Hospital
        • Principal Investigator:
          • Dianxun Fu, MD
        • Contact:
      • Tianjin, Tianjin Municipality, China, 300457
        • Recruiting
        • Teda International Cardiovascular Hospital
        • Contact:
        • Principal Investigator:
          • Weiqiang Wang, MM
      • Tianjin, Tianjin Municipality, China, 300211
        • Recruiting
        • The Second Hospital of Tianjin Medical University
        • Principal Investigator:
          • Changle Liu, MD
        • Contact:
    • Tibet
      • Chamdo, Tibet, China, 854000
        • Recruiting
        • Changdu People's Hospital of Tibet
        • Contact:
          • Rui Xiang, MD
          • Phone Number: 0895-4821745
        • Principal Investigator:
          • Rui Xiang, MD
    • Xinjiang
      • Yining, Xinjiang, China, 835000
        • Recruiting
        • Yili Kazak Autonomous Prefecture Friendship Hospital
        • Contact:
        • Principal Investigator:
          • Wei Li, MBBS
      • Ürümqi, Xinjiang, China, 830001
        • Recruiting
        • Xinjiang Uygur Autonomous Region People's Hospital
        • Contact:
        • Principal Investigator:
          • Guoliang Wang, PhD
    • Yunnan
      • Kunming, Yunnan, China, 650031
        • Recruiting
        • The First Affiliated Hospital of Kunming Medical University
        • Contact:
        • Principal Investigator:
          • Lihua Zhang, PhD
      • Kunming, Yunnan, China, 650102
        • Recruiting
        • Fuwai Yunnan Cardiovascular Hospital
        • Principal Investigator:
          • Zihong Guo, MD
        • Contact:
      • Kunming, Yunnan, China, 650051
        • Recruiting
        • Yan'an Affiliated Hospital of Kunming Medical University
        • Contact:
        • Principal Investigator:
          • Yan He, MD
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310000
        • Recruiting
        • Zhejiang Hospital
        • Principal Investigator:
          • Yimin Tang, MD
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

All patients with confirmed primary aldosteronism underwent adrenal venous sampling.

Description

Inclusion Criteria:

  1. Patients with confirmed primary aldosteronism;
  2. Patients undergoing adrenal venous sampling for subtype classification of primary aldosteronism.

Exclusion Criteria:

  1. Severe comorbidity, including stroke, myocardial infarction, heart failure, severe valvular heart disease, liver cirrhosis, and metastatic tumor within the previous 3 months；
  2. An estimated glomerular filtration rate <45 ml/min/1.73 m2, or serum creatinine >176 μmol/L；
  3. Patients who refuse adrenalectomy;
  4. Suspected of having an adrenocortical carcinoma;
  5. Allergy to contrast agent;
  6. Pregnant, nursing, or planning to become pregnant

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Adrenal Venous Sampling
Patients with Primary Aldosteronism (PA) undergoing Adrenal Venous Sampling via antecubital approach or femoral approach to discriminate PA forms with unilateral from bilateral excess aldosterone production.
Procedure: adrenal venous sampling
Patients with Primary Aldosteronism (PA) undergoing Adrenal Venous Sampling via antecubital approach or femoral approach to discriminate PA forms with unilateral from bilateral excess aldosterone production.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Major adverse cardiovascular events (MACE) at 1-year follow-up
Time Frame: 1 year after AVS procedure
Incidence of major adverse cardiovascular events (MACE) at 1-year follow-up, including stroke, heart failure, severe arrhythmias, renal failure, myocardial infarction, and death.
1 year after AVS procedure

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The success rate of bilateral adrenal venous sampling
Time Frame: At AVS procedure
Successful sampling will be defined by high selectivity index (cortisol in the adrenal vein/cortisol in inferior vena cava >2 without ACTH simulation)
At AVS procedure
The success rate of left adrenal venous sampling
Time Frame: At AVS procedure
Successful sampling will be defined by high selectivity index (cortisol in the adrenal vein/cortisol in inferior vena cava >2 without ACTH simulation)
At AVS procedure
The success rate of right adrenal venous sampling
Time Frame: At AVS procedure
Successful sampling will be defined by high selectivity index (cortisol in the adrenal vein/cortisol in inferior vena cava >2 without ACTH simulation)
At AVS procedure
Time of the procedure
Time Frame: At AVS procedure
Time of the procedure
At AVS procedure
Time of fluoroscopy
Time Frame: At AVS procedure
Time of fluoroscopy
At AVS procedure
The contrast agent dosage
Time Frame: At AVS procedure
The contrast agent dosage
At AVS procedure
the incidence of complications
Time Frame: 1 week after AVS procedure
Complications related to adrenal vein cannulations (adrenal vein hematoma, inferior vena cava dissection, puncture site hematoma, etc)
1 week after AVS procedure
the cost of the procedure
Time Frame: At AVS procedure
the cost of the procedure
At AVS procedure
Selection of intraoperative catheter
Time Frame: At AVS procedure
Types of catheter at the time of Adrenal Venous Sampling via antecubital approach or femoral approach
At AVS procedure
Change in 24-hour ambulatory systolic blood pressure
Time Frame: At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
The difference in average systolic blood pressure measured by 24-hour ambulatory blood pressure monitoring (ABPM) between baseline and each follow-up time point.
At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
Change in 24-hour ambulatory diastolic blood pressure
Time Frame: At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
The difference in average diastolic blood pressure measured by 24-hour ambulatory blood pressure monitoring (ABPM) bewteen baseline and each follow-up time point.
At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
Change in office systolic blood pressure
Time Frame: At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
The difference in systolic blood pressure measured during clinic visits (office blood pressure) between baseline and each follow-up time point
At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
Change in office diastolic blood pressure
Time Frame: At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
The difference in diastolic blood pressure measured during clinic visits (office blood pressure) between baseline and each follow-up time point
At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
Change in antihypertensive medication burden
Time Frame: At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
The change in the number and/or dosage of antihypertensive medications taken by patients between baseline and each follow-up time point
At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
Change in urinary albumin-to-creatinine ratio (UACR)
Time Frame: At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
The difference in urinary albumin-to-creatinine ratio measured at baseline and at each follow-up time point
At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
Change in left ventricular mass index (LVMI)
Time Frame: At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
The change in left ventricular mass index, as assessed by echocardiography, from baseline to each follow-up time point.
At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
Change in pulse wave velocity (PWV) from baseline
Time Frame: At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
The change in pulse wave velocity measured between baseline and each follow-up time point。
At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
Clinical Outcome According to Primary Aldosteronism Surgical Outcome (PASO) Criteria
Time Frame: At 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after surgery

Clinical outcomes will be assessed at each follow-up visit afteradrenal surgery according to the PASO consensus criteria. Outcomes will be categorized as:

(1)Complete clinical success: normal blood pressure without the need for any antihypertensive medication. (2)Partial clinical success: improvement in blood pressure and/or a reduction in the number or dosage of antihypertensive medications. (3)Absent clinical success: no improvement in blood pressure or antihypertensive medication burden.
At 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after surgery
Biochemical Outcome According to Primary Aldosteronism Surgical Outcome (PASO) Criteria
Time Frame: At 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after surgery
Biochemical outcomes will be assessed at each follow-up visit after adrenal surgery according to the PASO consensus classification. Outcomes will be categorized as:(1)Complete biochemical success: normal serum potassium levels and a normalized aldosterone-to-renin ratio (ARR) without the need for potassium supplementation.(2)Partial biochemical success: improvement in biochemical parameters without full normalization.(3)Absent biochemical success: no improvement in biochemical markers compared to baseline.
At 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after surgery
Major adverse cardiovascular events (MACE)
Time Frame: At 6 and 18 months; and 2, 3, 4, 5, and 10 years after AVS procedure
Incidence of major adverse cardiovascular events (MACE), including stroke, heart failure, severe arrhythmias, renal failure, myocardial infarction, and death.
At 6 and 18 months; and 2, 3, 4, 5, and 10 years after AVS procedure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Chinese Academy of Medical Sciences, Fuwai Hospital

Investigators

  • Principal Investigator: Hui Dong, MD, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2025

Primary Completion (Estimated)

August 31, 2029

Study Completion (Estimated)

August 31, 2029

Study Registration Dates

First Submitted

November 19, 2025

First Submitted That Met QC Criteria

November 19, 2025

First Posted (Actual)

November 26, 2025

Study Record Updates

Last Update Posted (Actual)

November 26, 2025

Last Update Submitted That Met QC Criteria

November 19, 2025

Last Verified

November 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2024-2484

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hyperaldosteronism

Clinical Trials on adrenal venous sampling

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe